Neoadjuvant immunotherapy treatment of localized genitourinary cancers : multidisciplinary management / Andrea Necchi, Philippe E. Spiess, editors.
Necchi, Andrea, editor.; Spiess, Philippe E., 1972- editor.
2022
RC280.G4 N46 2022
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Neoadjuvant immunotherapy treatment of localized genitourinary cancers : multidisciplinary management / Andrea Necchi, Philippe E. Spiess, editors.
ISBN 9783030805463 (electronic bk.)
3030805468 (electronic bk.)
9783030805456
303080545X
DOI https://doi.org/10.1007/978-3-030-80546-3
Published Cham : Springer, [2022]
Copyright ©2022
Language English
Description 1 online resource : illustrations (chiefly color)
Other Standard Identifiers 10.1007/978-3-030-80546-3 doi
Call Number RC280.G4 N46 2022
Dewey Decimal Classification 616.99/46
Summary This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians.
Note Includes index.
Access Note Access limited to authorized users.
Digital File Characteristics text file PDF
Source of Description Online resource; title from PDF title page (SpringerLink, viewed January 25, 2022).
Added Author Necchi, Andrea, editor.
Spiess, Philippe E., 1972- editor.
Available in Other Form Print version: 9783030805456
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Introduction
State-of-the art and ongoing developments
Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy
Slideshow of tumor samples before and after checkpoint inhibition
Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints
State-of-the-art and future role of molecular biomarkers for patient selection
Background of immunotherapy trials in prostate cancer
Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer
Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy
Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC
Benchmark of surgical safety results
What the scientific data tell us about predictive biomarkers of immunotherapy efficacy across the GU malignancies
Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies.

Browse Subjects

Show more subjects...

Statistics

from
to
Export